Lilly Sees More Dealmaking as GLP-1 Wins Expand Market
Eli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
Financial advisors offer valuable recommendations for new investors. Learn their insights to enhance your investment approach.
28,363 articlesEli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
Nebius Group shows a dramatic jump in revenue as AI demand accelerates. This article explains the drivers, checks the...
A seven-year high in regional bank M&A signals bigger players aiming for scale and efficiency. This guide breaks down...
Jaguar (JAGX) 2025 earnings show a company shifting from product-driven revenue to licensing cash. This piece breaks ...
Moderna’s growth story now centers on a broader mRNA pipeline and FDA decisions. This guide breaks down the upcoming ...
A large insider sale at Relay Therapeutics coincides with a dramatic stock rally. This article breaks down what the r...
Ford is plotting a bold move with ford's next generation electric—a scalable, low-cost EV platform designed to suppor...
Worried about the stock market as 2026 unfolds? This guide offers a clear, practical plan to manage risk, diversify, ...
Kalshi is courting a lofty valuation after a recent funding round, signaling confidence in prediction markets amid a ...
A tiny biotech just beat AbbVie's blockbuster in early-stage results, prompting fresh questions about the durability ...
Oil prices sprint higher, then pull back, leaving investors on edge. This piece explains how those moves could push i...
A 19% correction can spark questions about buying gold. This guide breaks down what history says, weighs physical gol...